

BENLYSTA

Please include the following to expedite the order:

Patient Demographics, Insurance Information, Labs

PATIENT

Referral Status: ☐ New ☐ Updated ☐ Renewal

Name: _____ DOB: _____ Gender: ☐ M ☐ F ☐ Other _____

Address: _____ City: _____ State: _____ Zip: _____ Phone: _____

PRESCRIBER

Name: _____ DEA: _____ NPI: _____ State License: _____

Address: _____ City: _____ State: _____ Zip: _____

Phone: _____ Fax: _____

CLINICAL

Diagnosis: ☐ M32.0 (Drug-Induced Systemic Lupus Erythema) ☐ M32.9 (Systemic Lupus Erythema)
☐ M32.8 (Other form of Systemic Lupus Erythema) ☐ Other: _____

Allergies: _____ Weight: _____ ☐ kg ☐ lbs Height: _____ ☐ cm ☐ in

Active Infection Present: ☐ Yes ☐ No

CBC Completed: ☐ Yes ☐ No CMP/LFTs Completed: ☐ Yes ☐ No Current flare: ☐ Yes ☐ No

TREATMENT

BENLYSTA (belimumab)

Route: Intravenous infusion

Dose: ☐ 10mg/kg ☐ Total Dose: _____ mg

Frequency:

☐ Induction: On weeks 0, 2, and 4

☐ Maintenance: Every 4 weeks

Premedication Protocol:

☐ Diphenhydramine: ☐ 25mg ☐ 50mg ☐ PO ☐ IV

☐ Acetaminophen: ☐ 325mg ☐ 500mg ☐ 650mg PO

☐ Other: _____

Sig: _____

☒ Center will use anaphylactic and hypersensitivity protocol established by Cure Stat Infusion Services.

Special Instructions: _____

Quantity: _____ Refills: _____

Provider Signature: _____

Date: _____